Skip to Content

FDA Approves Velcade

FDA Approves Velcade (bortezomib) for Multiple Myeloma

Velcade is an antineoplastic agent indicated for the treatment of multiple myeloma patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy.

Posted: May 2003

Related Articles:

View comments